Scheltens, Philip

EFNS ‐ ENS / EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 140

Progression of Mild Cognitive Impairment to Dementia: Contribution of Cerebrovascular Disease Compared With Medial Temporal Lobe Atrophy

Staekenborg, S. S., Koedam, E. L. G. E., Henneman, W. J. P., Stokman, P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2009) · Stroke

Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and Treatments

Cited by 139

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 137

An algorithmic approach to structural imaging in dementia

Harper, L., Barkhof, F., Scheltens, P., Schott, J. M., & Fox, N. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchRadiology practices and education

Cited by 137

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

Swarup, V., Hinz, F. I., Rexach, J. E., Noguchi, K.-I., Toyoshiba, H., Oda, A., Hirai, K., Sarkar, A., Seyfried, N. T., Cheng, C., et al. (2019) · Nature Medicine

Alzheimer's disease research and treatmentsBioinformatics and Genomic Networks

Cited by 136

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Trajectories of cognitive decline in different types of dementia

Smits, L. L., van Harten, A. C., Pijnenburg, Y. A. L., Koedam, E. L. G. E., Bouwman, F. H., Sistermans, N., Reuling, I. E. W., Prins, N. D., Lemstra, A. W., Scheltens, P., et al. (2015) · Psychological Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 134

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 132

Single-Subject Grey Matter Graphs in Alzheimer's Disease

Tijms, B. M., Möller, C., Vrenken, H., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., & Barkhof, F. (2013) · PLoS ONE

Functional Brain Connectivity StudiesDementia and Cognitive Impairment Research

Cited by 132

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., et al. (2018) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 129

The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia

Bastos-Leite, A. J., van der Flier, W. M., van Straaten, E. C. W., Staekenborg, S. S., Scheltens, P., & Barkhof, F. (2007) · Stroke

Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and Treatments

Cited by 128

The Alzheimer’s disease drug development landscape

van Bokhoven, P., de Wilde, A., Vermunt, L., Leferink, P. S., Heetveld, S., Cummings, J., Scheltens, P., & Vijverberg, E. G. B. (2021) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 123

Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement.

Ossenkoppele, R., Zwan, M. D., Tolboom, N., van Assema, D. M. E., Adriaanse, S. F., Kloet, R. W., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., et al. (2012) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 123

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

DESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 120

Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Zwan, M. D., Bouwman, F. H., Konijnenberg, E., van der Flier, W. M., Lammertsma, A. A., Verhey, F. R. J., Aalten, P., van Berckel, B. N. M., & Scheltens, P. (2017) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 118

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., Molinuevo, J. L., Wallin, A., Lleó, A., Popp, J., et al. (2018) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 112

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease

Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 112

Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia

Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., & van Berckel, B. N. M. (2013) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 112

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 110

Whole-brain atrophy rate in Alzheimer disease: Identifying fast progressors

Sluimer, J. D., Vrenken, H., Blankenstein, M. A., Fox, N. C., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2008) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 110

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study

Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 106

Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis

Möller, C., Pijnenburg, Y. A. L., van der Flier, W. M., Versteeg, A., Tijms, B., de Munck, J. C., Hafkemeijer, A., Rombouts, S. A. R. B., van der Grond, J., van Swieten, J., et al. (2016) · Radiology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 103

Heterogeneity of Alzheimer’s disease: consequence for drug trials?

Devi, G., & Scheltens, P. (2018) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 102